Corpus Intelligence IC Memo — BAYLOR S&W MEDICAL CENTER - IRVING 2026-04-26 17:23 UTC
IC Memo — BAYLOR S&W MEDICAL CENTER - IRVING
Investment Committee Memorandum | TX | 205 beds | Grade C | EBITDA uplift $18.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BAYLOR S&W MEDICAL CENTER - IRVING

CCN 450079 | nan, TX | 205 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

BAYLOR S&W MEDICAL CENTER - IRVING is a 205-bed suburban community hospital in nan, TX with $244.7M in net patient revenue and a -12.8% operating margin. The hospital serves a payer mix of 18.8% Medicare, 3.1% Medicaid, and 78.1% commercial.

Thesis: Undervalued. Our ML models identify $18.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -12.8% to -5.5% (+736bps).

Net Revenue HCRIS$244.7M
Current EBITDA COMPUTED$-31.4M
Operating Margin COMPUTED-12.8%
Occupancy HCRIS75.3%
Revenue / Bed COMPUTED$1.2M
Net-to-Gross HCRIS23.5%
Distress Probability ML41.3%

2. Market Context & Competitive Position

583
TX Hospitals
-0.7%
State Median Margin
148
Comparable Hospitals

TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of -12.8% places it below the state median. Among 148 size-comparable peers (102-410 beds), the median margin is 4.9%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (102-410), prioritizing same-state peers. 148 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BAYLOR S&W MEDICAL CENTER - IR (Target)TX205$244.7M-12.8%
CHILDRENS MEDICAL CENTER OF DATX377$1.56B10.3%
DELL CHILDRENS MEDICAL CENTERTX262$901.9M25.5%
DOCTORS HOSPITAL AT RENAISSANCTX394$847.8M9.2%
ASCENSION SETON MEDICAL CENTERTX391$702.5M12.6%
DRISCOLL CHILDRENS HOSPITALTX215$694.3M29.4%
ROUND ROCK HOSPITALTX165$681.4M8.7%
METHODIST SUGAR LAND HOSPITALTX337$679.6M12.6%
METHODIST WILLOWBROOK HOSPITALTX346$661.8M10.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $18.0M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$5.1M+210bp18mo
Cost to Collect4.5%2.5%$4.9M+200bp12mo
Denial Rate Reduction12.0%6.5%$4.8M+198bp12mo
A/R Days Reduction5200.0%3800.0%$3.0M+122bp9mo
Clean Claim Rate88.0%96.0%$157K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$5.1M
Cost to Collect
$4.9M
Denial Rate Reduction
$4.8M
A/R Days Reduction
$3.0M
Clean Claim Rate
$157K
Total EBITDA Uplift$18.0M
Current EBITDA$-31.4M
+ RCM Uplift+$18.0M
Pro Forma EBITDA$-13.4M
Current Margin-12.8%
Pro Forma Margin-5.5%
WC Released (1x)$9.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-48.3M$-27.0M0.00x-100.0%
Base (11x exit)10.0x11.0x$-48.3M$-45.4M0.00x-100.0%
Bull Case9.0x11.0x$-43.5M$-1.6M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-43.5M$-14.6M0.00x-100.0%
Bear Case11.0x10.0x$-53.1M$-101.3M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-53.1M$-128.7M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 148 hospitals with 102-410 beds
  • Same-state prioritization (n=149)
  • Comp margins: P25=-6.7% / P50=4.9% / P75=13.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.